Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $4.75 million. The enterprise value is -$2.86 million.
Important Dates
The next estimated earnings date is Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 4.48 million shares outstanding. The number of shares has increased by 3.81% in one year.
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | +3.81% |
| Shares Change (QoQ) | +6.48% |
| Owned by Insiders (%) | 4.13% |
| Owned by Institutions (%) | 2.13% |
| Float | 4.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.83 |
| Forward PS | n/a |
| PB Ratio | 0.66 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.84
| Current Ratio | 5.84 |
| Quick Ratio | 5.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -751.85 |
Financial Efficiency
Return on equity (ROE) is -48.34% and return on invested capital (ROIC) is -33.50%.
| Return on Equity (ROE) | -48.34% |
| Return on Assets (ROA) | -26.11% |
| Return on Capital (ROIC) | -33.50% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.17M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.65% in the last 52 weeks. The beta is 1.36, so Silo Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -37.65% |
| 50-Day Moving Average | 1.12 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 43.22 |
| Average Volume (20 Days) | 124,405 |
Short Selling Information
The latest short interest is 67,438, so 1.50% of the outstanding shares have been sold short.
| Short Interest | 67,438 |
| Short Previous Month | 134,766 |
| Short % of Shares Out | 1.50% |
| Short % of Float | 1.57% |
| Short Ratio (days to cover) | 1.87 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$3.51 million in losses. Loss per share was -$1.18.
| Revenue | 72,102 |
| Gross Profit | 66,264 |
| Operating Income | -3.82M |
| Pretax Income | -3.60M |
| Net Income | -3.51M |
| EBITDA | n/a |
| EBIT | -3.82M |
| Loss Per Share | -$1.18 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 7.61M |
| Total Debt | n/a |
| Net Cash | 7.61M |
| Net Cash Per Share | $1.70 |
| Equity (Book Value) | 5.96M |
| Book Value Per Share | 1.60 |
| Working Capital | 6.41M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.55M |
| Capital Expenditures | n/a |
| Free Cash Flow | -3.55M |
| FCF Per Share | -$0.79 |
Full Cash Flow StatementMargins
| Gross Margin | 91.90% |
| Operating Margin | -5,297.23% |
| Pretax Margin | -4,778.21% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -4,673.92% |